This evaluation supports its use in combination with targeted therapies, e.g., with cetuximab (an anti-EGFR antibody) in squamous cell carcinoma of the head and neck (HNSCC), whereas a 30% objective response rate (ORRs) was observed. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.